Search

Ranolazine

[A189234] Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. … [L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440]

Bremelanotide

[A179689] Bremelanotide was granted FDA approval on 21 June 2019.[L9635] … [A179686] The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown.

Kojic acid

Voxelotor

The EMA approved the use of voxelotor for the treatment of hemolytic anemia associated with sickle cell disease in February 2022.[L41419,L41424] … Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease.

Dimetacrine

Dimetacrine is also known as dimethacrine or acripamine. It is marketed under the names Istonil, Istonyl, Linostil, and Miroistonil. … Dimetacrine is a tricyclic antidepressant (TCA) with imipramine-like effects used in Europe for the treatment of depression. Dimetacrine is no longer used in Japan.

Riltozinameran

The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. … [L43917] As of November 2022, it is the primary circulating variant of concern according to the World Health Organization.

Zongertinib

[L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain

Avalglucosidase alfa

[L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of patients older than six months of age with late-onset Pompe disease. … cellular uptake of the drug and better muscle targeting.

Encorafenib

melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. … [L3344] On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic

Buserelin

Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR).